Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

ALS Untangled says tamoxifen is not yet supported as an ALS treatment

Original source

TamoxifenALSUntangled · 1 February 2021 (opens in a new tab)

An ALS Untangled review found that tamoxifen has plausible mechanisms and at least one positive preclinical study related to ALS. One case report and two small human trials suggested slower disease progression with higher doses, but the evidence is not sufficient to recommend tamoxifen for treatment.

Why this matters

This information may interest people with ALS and their clinicians, but it does not establish that tamoxifen works or should be used for ALS. A larger human clinical trial, including research on an 80-milligram daily dose, is needed.

Limitations and context

The evidence described consists of a case report, two small human trials and preclinical research. The source is an expert review, not a new clinical trial, and it reports associations rather than establishing that tamoxifen slows ALS progression. The review also mentions a study suggesting lower ALS risk, but says this finding needs independent replication.

Summarised by Compass 10 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?